Robeco Institutional Asset Management B.V. Sells 507,124 Shares of Zoetis Inc. $ZTS

Robeco Institutional Asset Management B.V. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 93.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,324 shares of the company’s stock after selling 507,124 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Zoetis were worth $5,608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Scott & Selber Inc. raised its stake in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after purchasing an additional 67 shares in the last quarter. North Star Asset Management Inc. raised its position in shares of Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after buying an additional 67 shares in the last quarter. Secure Asset Management LLC lifted its holdings in shares of Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares during the last quarter. Moment Partners LLC grew its position in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after acquiring an additional 72 shares in the last quarter. Finally, CVA Family Office LLC increased its stake in Zoetis by 6.7% during the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after acquiring an additional 74 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.2%

NYSE:ZTS opened at $127.10 on Friday. The company has a market cap of $56.01 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 2.59 and a beta of 0.97. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a fifty day simple moving average of $123.29 and a 200-day simple moving average of $140.60.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the business posted $1.58 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Stifel Nicolaus lowered their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.